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morbidity and treatment variables updated over time.
Background. The objective of this study was to gain insight
into the associations of anemia with mortality among mainte-
nance hemodialysis (HD) patients and patient subgroups by
an analysis that more comprehensively represents hemoglobin
(Hb) level, morbidity, and treatment characteristics over time
than was possible in prior observational studies.
Methods. A cohort study was conducted among 5517 subjects
in the American arm of the Dialysis Outcomes and Practice Pat-
terns Study Phase I. We used proportional hazard analysis to
model all-cause mortality as a function of Hb level measured 1,
3, and 6 months previously. Forty-five potentially confounding
patient-level characteristics were considered, including demo-
graphics, comorbidities, and time-updated levels of erythropoi-
etin and parenteral iron dosing, medical events, and laboratory
and dialysis measures.
Results. Compared to Hb 11 to <12 g/dL, subjects with Hb
<11 g/dL had increased mortality [adjusted hazard ratios (95%
confidence interval) in the 3-month-lagged model = 1.74 (1.24
to 2.43) for <9 g/dL, 1.25 (0.96 to 1.63) for 9 to <10 g/dL, and
1.22 (0.99 to 1.49) for 10 to <11 g/dL categories]. Mortality
rates for subjects with Hb 12 to <13 g/dL and ≥ 13 g/dL did
not differ significantly from those with Hb 11 to <12 g/dL. The
relationships between Hb and mortality varied modestly with
changes in the time interval between Hb measurement and the
time at risk for mortality, but did not vary according to ESRD
vintage or health status indicators.
Conclusion. Our findings confirm the associations of Hb lev-
els ≥11 g/dL with longer survival among maintenance HD pa-
tients, but show no additional survival advantage for patients
with Hb levels ≥12 g/dL. Further investigation of the rela-
tionships among anemia, treatment of anemia, and survival is
warranted.
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It is estimated that 95% of patients undergoing main-
tenance hemodialysis (HD) for end-stage renal disease
(ESRD) receive treatment for anemia [1, 2]. According
to Medicare billing data, mean hemoglobin (Hb) level
among prevalent HD patients increased from 9.5 g/dL
in 1991 to 11.7 g/dL in 2002, and mean recombinant hu-
man erythropoietin (epoetin) dose and parenteral iron
use have risen markedly over the same period. The
increased intensity of anemia management among HD
patients has been, in large part, a response to clinical
practice guidelines based on structured literature reviews
[3, 4]. Nonetheless, the optimal Hb level above 10 g/dL
remains controversial [3–6], in large part because the
results of observational studies examining outcomes ac-
cording to achieved Hb levels [7–15] contrast with clinical
trial outcomes according to randomized target Hb levels
[16–26].
Although clinical trials have reported disparate effects
of target Hb levels higher than 10 g/dL on physiologic
measures [17–21, 23] and quality of life [21, 22, 24, 25],
a major multicenter clinical trial of maintenance HD pa-
tients with cardiac disease was halted early due to a trend
toward higher mortality among subjects randomized to
hematocrit (Hct) of 42% than among subjects random-
ized to Hct of 30% [16]. Based in large part on that study,
the authors of a recent meta-analysis concluded that the
benefits of higher Hb targets are outweighed by the risks
among chronic kidney disease (CKD) patients with car-
diac disease, and that there are insufficient data to guide
choice of Hb targets among those without cardiac disease
[26].
On the other hand, observational analyses of large ad-
ministrative HD databases have found that, compared
to patients with achieved Hb levels of 10 to 11 g/dL,
those with Hb 11 to 12 g/dL have decreased morbidity
[11–13, 15] and mortality [9, 11–13], and those with Hb
≥12 g/dL may have yet greater survival [12, 13]. Despite
the almost certain influence of these studies on published
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clinical guidelines for target Hb level and on anemia
management protocols in many HD facilities, it is highly
plausible that the associations they report may not reflect
a causal link between anemia and poor outcomes because
of confounding by incompletely measured health status
or aspects of delivered dialysis care that independently
increase both mortality and resistance to epoetin ther-
apy [3, 4, 11]. Additionally, the exclusive reliance in these
studies on “baseline” Hb levels to model mortality over a
subsequent extended or physiologically arbitrary period
of follow-up may distort associations during any shorter
time interval when Hb may be most strongly associated
with, or directly affect, mortality [27].
To explain in part the discrepancies between the clini-
cal trials and observational studies, we hypothesized that
the associations of higher achieved Hb levels with longer
survival in prior observational studies would be less ap-
parent in an analysis that more comprehensively repre-
sents Hb and potentially confounding variables. We have
addressed this hypothesis with analyses of the Ameri-
can arm of the Dialysis Outcomes and Practice Patterns
Study (DOPPS) Phase I, a large contemporary cohort of
HD patients for which Hb levels and detailed morbid-
ity were available at study entry and for up to 5 years of
follow-up.
METHODS
The DOPPS
The DOPPS Phase I was conducted between 1996 and
2001. A complete description of its design has been pub-
lished [28]. In the United States, 142 maintenance HD fa-
cilities were selected by stratified random sampling based
on the 1996 adjusted mortality ratio to achieve variation
in practice patterns and outcomes. At the start of the
project, random samples of 20 to 40 patients per facility
were selected. Patients subsequently terminating care at a
participating facility were replaced approximately every
4 months, using random selection from patients enter-
ing the facility during the interval. Therefore, the initial
cross-sectional sample was enriched over time with pa-
tients relatively new to dialysis.
Patient-level DOPPS data were abstracted from the
medical record, supplemented by personal knowledge,
by a study coordinator in each participating HD facil-
ity. Pertinent to this analysis were a detailed enrollment
medical summary and interval medical summaries com-
pleted approximately every 4 months until departure
from the DOPPS. Laboratory and dialysis prescription
data recorded were the most recent values obtained prior
to each medical summary. Epoetin dosing was character-
ized by total units in the most recent week prior to each
medical summary, and parenteral iron dosing was char-
acterized by cumulative dose since the most recent prior
medical summary. Dates and details of hospitalizations,
outpatient medical interventions, vascular access events,
and departures were recorded.
Study data
Mortality and censoring events. The outcome for our
study was all-cause mortality. Censoring events included
termination of care at a participating DOPPS facility, or
the end of the DOPPS Phase I.
Hemoglobin exposure. We incorporated time-varying
Hb measures into our analytic models. To examine the
possibility that the association of Hb level with mortality
may change as the interval between Hb level and the
time at risk for mortality varies, we considered mortality
in 3 separate models as a function of Hb level “lagged”
1, 3, or 6 months before the start of the time at risk for
mortality (“1-, 3-, and 6-month-lagged models”). We did
not examine the impact of Hb on mortality according to
Hb level lagged more than 6 months before the start of
the time at risk for mortality because of the limitations of
the data and, therefore, statistical power.
Potentially confounding variables. Table 1 lists the
potentially confounding variables that we evaluated for
inclusion in our survival models. Demographic and co-
morbidity variables recorded at DOPPS enrollment were
considered, as were variables representing the total
number of inpatient hospital days, hospital admissions,
vascular access procedures, and other outpatient medi-
cal procedures over the 3 months immediately prior to
the date of each time-updated Hb value. To avoid bias
that might be induced by controlling for values of labo-
ratory, dialysis, and medication variables measured con-
currently with or soon after each Hb level [29–31], we
adjusted our analyses for the most recent values of these
variables recorded prior to the date of each time-updated
Hb level. Both continuous and categorical treatments of
continuous variables were considered.
Subject eligibility. Because of the above assump-
tions, Hb values “qualifying” for our analyses (1) were
measured at least 3 months after DOPPS enrollment
(enabling characterization of prior hospitalizations and
medical events for the 3 most recent months); (2) were
preceded by at least 1 prior laboratory date (enabling
characterization of most recent prior laboratory, dialysis,
and medication variables); and (3) were measured at least
1, 3, or 6 months before death or censoring (for the 1-, 3-,
and 6-month-lagged models, respectively). All DOPPS
subjects with at least 1 Hb value meeting these criteria
were eligible for the analyses.
Statistical methods
Our analyses of the probability of mortality as a func-
tion of Hb level used Cox proportional hazards models
with time-dependent covariates [32]. For each subject,
the total time at risk was from 1, 3, or 6 months after the
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Table 1. Variables considered to plausibly confound the association
of hemoglobin with mortality
Recorded at DOPPS enrollment
Demographics
Sex
Race/ethnicity
ESRD cause
Morbidity and other characteristicsa
Atherosclerotic cardiovascular disease
Congestive heart failure
Hypertension
Left ventricular hypertrophy
Cancer, non-skin
Gastrointestinal illness
Neurologic illness
Pulmonary illness
Psychiatric illness
Smoking history
Do-not-resuscitate status
Functional status (ordered variable)
Updating during each DOPPS intervalb
Demographics
Age
ESRD vintage (years since first HD)
Laboratory measures
Albumin
Bicarbonate
Calcium
Calcium-phosphate product
Cholesterol, total
Creatinine
Ferritin
Hemoglobin (prior)
Parathyroid hormone
Phosphate
Potassiumd
Transferrin saturation
White blood cell count
Medications
Epoetin dose (units/week)
Epoetin administration route (intravenous or subcutaneous)
Parenteral iron dose (normalized 6-month cumulative)
Parenteral iron administrations (normalized 6-month cumulative)
Dialysis parameters
HD duration, delivered
HD duration, prescribed
Systolic blood pressure, predialysis
Systolic blood pressure, postdialysis
Kt/V, delivered
Urea reduction ratio, delivered
Ultrafiltration volume, removed
Other
Kidney transplantation, active listing for
Nutritional supplement, currently prescribed
Residual renal functiond
Medical eventsc
Hospitalized days
Hospitalizations
Outpatient medical procedures
Vascular access procedures
Consideration for multivariable model inclusion: ESRD vintage was the des-
ignated time scale for our survival models. All other variables listed above were
tested for P ≤ 0.10 for the association with mortality in the adjusted 3-month-
lagged model. Those variables designated by bold type met this criterion and were
included in all adjusted models.
aDichotomous (yes/no) unless otherwise indicated.
bSee text for methods used by the DOPPS to update variables. In our multi-
variable models, levels of time-updated potentially confounding variables were
the most recent values prior to time-updated Hb levels.
cCumulative over most recent 3 months.
dVariables for smoking history, potassium level, and residual renal function had
P > 0.20 for the unadjusted association with mortality.
date of the earliest qualifying Hb level (for the 1-, 3-, and
6-month-lagged models, respectively) until death or cen-
soring. Because modeling survival in prevalent cohorts
using biologically arbitrary time scales such as days since
study entry can be subject to left-truncation bias [33], we
used days since onset of ESRD (ESRD vintage) as the
time scale. We stratified by center to account for the pos-
sibility of systematic, otherwise uncaptured, differences
among the DOPPS facilities.
The following model-building strategy was applied to
our 3-month-lagged model. We first described the unad-
justed associations with mortality of the variables listed
in Table 1. All covariates for which the unadjusted asso-
ciation with mortality had P ≤ 0.20 were entered into a
multivariable survival model. We fit a final model by using
backward elimination to sequentially exclude covariates
for which the association with mortality had P > 0.10 [34,
35]. For our 1- and 6-month-lagged models, we modeled
mortality by Hb level, adjusting for prior levels of the
covariates included in the final 3-month-lagged model.
Unless otherwise stated, P < 0.05 was the criterion for
statistical significance. All analyses used Stata version 7
[36].
RESULTS
Subject eligibility
Nine thousand one hundred and two subjects partic-
ipated in the American arm of the DOPPS Phase I. Of
these, (1) 7300 subjects had 1 or more Hb value measured
at least 3 months after DOPPS enrollment; (2) of these,
7104 had 1 or more Hb value that was also preceded by
a prior laboratory date; and (3) of these, 6167, 5517, and
4610 subjects were eligible for the 1-, 3-, and 6-month-
lagged models, respectively, because they had 1 or more
Hb value that (in addition to satisfying criteria 1 and 2)
was measured at least 1, 3, or 6 months before death or
censoring.
Descriptive analyses
Among the 5517 subjects eligible for the 3-month-
lagged model, the median time between onset of ESRD
and the earliest qualifying Hb value was 1.3 years (25th
percentile 0.5 years; 75th percentile 3.3 years; range 0.25
to 30.4 years). For the 3-month-lagged model, the time at
risk began 3 months after the earliest qualifying Hb value.
The median total time at risk was 13.4 months (range 0.2
to 53.0 months), the total person-time at risk was 7341
years, there were 1906 deaths, and the death rate was
0.26 per year.
Table 2 shows the categorized distribution of the ear-
liest qualifying Hb levels among all eligible subjects. The
mean and median Hb levels were both 11.2 g/dL. The
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Table 2. Distributions of demographics and anemia management variables for eligible subjects (N = 5517)
Stratum-specific distribution (%) by hemoglobin level g/dLOverall distribution
N (%) <11 11–<12 >12 P valuea
Hemoglobin level
Hb g/dLb
<9 363 (6.6) – – – –
<10 639 (11.6) – – –
10 to <11 1342 (24.3) – – –
11 to <12 1628 (29.5) – – –
12 to <13 1010 (18.3) – – –
≥13 535 (9.7) – – –
Demographics
Yearc
1996 to 1998 3272 (59.3) 49.3 30.8 19.9 <0.001
1999 to 2001 2245 (40.7) 32.6 27.6 39.9
Age (years)c
18 to <40 647 (11.7) 43.9 26.0 30.1 0.16
40 to <60 1771 (32.1) 42.0 31.1 26.9
≥60 3098 (56.2) 42.5 29.3 28.2
Race/ethnicity
Non-Hispanic black 1973 (35.8) 46.3 28.9 24.8 0.001
Hispanic 560 (10.1) 40.5 30.4 29.1
Non-Hispanic white 2671 (48.4) 40.3 29.7 30.0
Other 313 (5.7) 40.9 30.0 29.1
Sex
Female 2506 (45.4) 45.9 28.9 25.2 <0.001
Male 3011 (54.6) 39.6 30.0 30.4
Cause of ESRD
Diabetes 2116 (40.4) 41.2 30.0 28.8 0.03
Hypertension 1622 (31.0) 44.0 30.6 25.4
Glomerulonephritis 576 (11.0) 40.6 30.9 28.5
Other 919 (17.6) 47.0 26.8 26.2
Years since first HDc
0 to <0.25 2318 (42.0) 37.3 28.0 34.7 <0.001
0.25 to <2 1420 (25.7) 44.7 32.5 22.8
≥2 1779 (32.3) 47.5 29.1 23.4
Administered medicationsc
Epoetin units/week
0 375 (8.3) 21.8 28.7 49.5 <0.001
>0 to 10,000 1558 (34.3) 32.6 35.2 32.3
>10,000 to 30,000 2284 (50.2) 40.4 30.5 29.1
>30,000 331 (7.3) 50.0 24.4 25.7
Epoetin route
Intravenous 4672 (88.8) 37.0 32.0 31.0 0.001
Subcutaneous 589 (11.2) 39.0 28.1 32.8
IV iron (mg/6 months)
0 to 1000 2577 (60.0) 36.8 31.1 32.1 0.11
>1000 1715 (40.0) 35.5 32.4 32.2
Laboratory measures (blood)c
Ferritin ng/dL
<100 1170 (22.7) 34.8 31.2 34.0 <0.001
100 to <800 3446 (67.0) 36.7 32.1 31.2
≥800 528 (10.3) 42.0 28.2 29.9
TSAT (%)
<20 1910 (37.5) 37.2 31.3 31.5 0.10
20 to <50 2793 (54.8) 36.6 32.1 31.4
≥50 393 (7.7) 38.6 28.7 32.7
aBy chi-square test for heterogeneity.
bEarliest Hb level qualifying for multivariable analyses.
cAt DOPPS enrollment.
distribution of Hb levels 1 year after DOPPS enrollment
was similar (data not shown). Table 2 also provides the
distribution of selected demographic characteristics and
anemia management variables at enrollment, and the dis-
tribution of Hb levels by these variables.
In unadjusted proportional hazard analyses examin-
ing mortality in the 3-month-lagged model, hazard ratios
[95% confidence interval (CI)] compared to Hb lev-
els 11 to <12 g/dL were 1.80 (1.46–2.22) for Hb levels
<9 g/dL; 1.24 (1.04–1.48) for Hb levels 9 to <10 g/dL; 1.11
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Table 3. Adjusteda hazard ratios for mortality by hemoglobin level in
the 3-month-lagged model (N = 3352b)
Reference Hb category 11–<12 g/dL
Hb level g/dL HR (95% CI)
<9 1.74 (1.24–2.43)
9 to <10 1.25 (0.96–1.63)
10 to <11 1.22 (0.99–1.49)
11 to <12 Ref.
12 to <13 0.90 (0.73–1.13)
≥13 1.04 (0.79–1.36)
P valuec 0.005
Reference Hb category 11–<13 g/dL
Hb level g/dL HR (95% CI)
<9 1.80 (1.29–2.49)
9 to <10 1.29 (1.01–1.67)
10 to <11 1.26 (1.04–1.52)
11 to <13 Ref.
≥13 1.08 (0.83–1.40)
P valuec < 0.001
aAdjusted for variables denoted by bold type in Table 1.
bNumber of eligible subjects with complete covariate characterization.
cBy the Wald test for an overall inverse correlation.
(0.97–1.27) for Hb levels 10 to <11 g/dL; 0.85 (0.73–0.99)
for Hb levels 12 to <13 g/dL; and 0.92 (0.76–1.12) for
Hb levels ≥13 g/dL (overall P value < 0.001). Among the
variables in Table 1, all except smoking history, potassium
level, and residual renal function had P value ≤ 0.20 for
the unadjusted association with mortality.
Multivariable analyses
Three-month-lagged model. Table 3 provides the ad-
justed hazard ratios for mortality by Hb level in the 3-
month-lagged model. Subjects with Hb levels <11 g/dL
had elevated mortality [HR (95% CI) 1.74 (1.24 to 2.43)
for <9 g/dL, 1.25 (0.96 to 1.63) for 9 to <10 g/dL, and 1.22
(0.99 to 1.49) for 10 to <11 g/dL categories] compared to
subjects with Hb levels 11 to <12 g/dL. Mortality rates
for subjects with Hb levels 12 to <13 g/dL and ≥13 g/dL
were not significantly different than for subjects with Hb
levels 11 to <12 g/dL. The other covariates that remained
in the final multivariable model (P ≤ 0.10) are indicated
in Table 1.
As a test of proportionality of hazards, we found no
detectable interaction between categorized Hb level and
ESRD vintage (P = 0.39 for untransformed and P = 0.24
for log-transformed vintage by likelihood-ratio test). As
evidence that the 3352 subjects in the final adjusted model
were representative of the 5517 eligible subjects, a vari-
able designating “missingness” of at least 1 covariate in
the final adjusted model was not significantly associated
with mortality in models with all eligible subjects that
were unadjusted [P = 0.24, HR (95% CI) 0.93 (0.83 to
1.05)] or adjusted for covariates for which characteriza-
tion was complete [Hb level, baseline characteristics, and
hospitalization data; P = 0.24, HR (95% CI) 0.93 (0.83 to
1.05)].
Possible effect modiﬁcation by health status. To ex-
amine the possibility that the associations of ane-
mia with increased mortality might vary according to
level of morbidity or acute illness, we tested for in-
teractions of Hb with indicators of health status. No
statistically significant interactions were found for the
associations of time-updated Hb level with ESRD vin-
tage (above) baseline; with cardiovascular disease (CVD)
(P = 0.43); with most recent prior albumin (P =
0.20), creatinine (P = 0.40), ferritin (P = 0.90), or hemo-
globin (P = 0.24) levels; with most recent epoetin dose
(P = 0.08); or with the number of inpatient hospital days
over the most recent 3 months (P = 0.11). P values listed
are for interactions of Hb level with dichotomous ver-
sions of these variables; other approaches yielded similar
findings.
Widening the Hb target range. It has been suggested
that the NKF-K/DOQI’s target Hb range of 11 to 12 g/dL
is too narrow to allow for natural distribution of Hb values
at the patient or population levels [37, 38]. We therefore
repeated the 1-, 3-, and 6-month-lagged analyses using 11
to <13 g/dL rather than 11 to <12 g/dL as the reference
range. As listed in Table 3, the magnitude of the associ-
ations of categorized Hb levels <11 g/dL with mortality
were comparable to those using 11 to <13 g/dL as the
reference range, but all hazard ratios for Hb levels <11
g/dL were now statistically significant. Mortality did not
differ significantly between the 11 to <13 g/dL and the
≥13 g/dL categories.
Comparisons between the 1-, 3-, and 6-month-lagged
models. Table 4 illustrates variations in the association
of Hb level with mortality according to changes in the in-
terval between Hb level and the time at risk for mortality.
Compared to Hb 11 to <12 g/dL, elevated mortality for
Hb categories <11 g/dL changed little as this time inter-
val changed. For Hb levels ≥12 g/dL, mortality rates were
similar to Hb 11 to <12 g/dL in the 1- and 3-month-lagged
models. In the 6-month-lagged model, subjects with Hb
levels 12 to <13 g/dL and ≥13 g/dL had hazard ratios
(95% CI) for mortality of 0.80 (0.63 to 1.02) and 0.79
(0.58–1.08) compared to subjects with Hb levels 11 to
<12 g/dL.
Other analyses. In a separate series of models, the haz-
ard ratios for the adjusted probability of mortality as a
function of mean Hb level during 6-month windows ei-
ther 1 to 7, 3 to 9, or 6 to 12 months previously were not
substantially different than those reported above for our
1-, 3-, and 6-month-lagged models, respectively.
DISCUSSION
Prior relationships described in observational studies
between higher achieved Hb level and lower mortality
in maintenance HD patients [7–15] might be biased by
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Table 4. Adjusteda hazard ratios for mortality by hemoglobin level in the 1-, 3-, and 6-month-lagged models (N = 2790b)
Hemoglobin 1 month previously Hemoglobin 3 months previously Hemoglobin 6 months previously
Hemoglobin level g/dL
<9 1.69 (1.14–2.49) 1.62 (1.09–2.40) 1.59 (1.06–2.37)
9 to <10 1.46 (1.07–2.00) 1.21 (0.90–1.64) 1.27 (0.95–1.72)
10 to <11 1.23 (0.97–1.56) 1.28 (1.02–1.62) 1.21 (0.97–1.50)
11 to <12 Ref. Ref. Ref.
12 to <13 0.97 (0.76–1.24) 0.90 (0.70–1.16) 0.80 (0.63–1.02)
≥ 13 1.10 (0.81–1.49) 1.04 (0.77–1.40) 0.79 (0.58–1.08)
P valuec 0.02 0.03 0.001
aAdjusted for variables denoted by bold type in Table 1.
bFor all 3 models, these analyses were restricted to the 2790 eligible subjects with complete covariate characterization for the 6-month-lagged model.
cBy the Wald test for an overall inverse correlation.
incomplete characterization of Hb level and patient or
treatment characteristics that influence Hb level over
time. To address this possibility, we conducted an anal-
ysis of the association of Hb level with mortality in the
American arm of the DOPPS Phase I that incorporated
detailed baseline comorbidity and time-updated levels of
Hb, epoetin and parenteral iron dosing, medical events,
and laboratory and dialysis measures. Our principal find-
ings were that (1) Hb levels <11 g/dL were associated
with elevated mortality compared to Hb levels ≥11 g/dL,
(2) Hb levels ≥12 g/dL were associated with survival that
is at least as favorable as for Hb levels 11 to 12 g/dL, (3)
the relationships between anemia and mortality changed
modestly as the time interval between measured Hb and
the time at risk for mortality widened, and (4) the rela-
tionships between anemia and mortality did not change
according to ESRD vintage or indicators of health status.
Despite key methodologic differences, findings (1) and
(2) are consistent with prior analyses of administrative
databases that characterized the relationship of Hb or Hct
value during a baseline period to mortality over subse-
quent follow-up. Several analyses used Medicare/Center
for Medicare and Medicaid Services claims data adjusted
for demographics, comorbidities at the start of ESRD,
and baseline period “disease severity indicators,” includ-
ing number of blood transfusions, access procedures, and
hospitalization days [9, 11–13]. An analysis of Fresenius
Medical Corporation North America (FMCNA) data was
adjusted for demographics, missed treatments, and base-
line albumin, ferritin, and TSAT levels [12]. Contrary to
our hypothesis, we did not find that the associations of
higher achieved Hb levels with lower mortality in these
prior observational studies were less apparent in our anal-
ysis that accounted substantially more comprehensively
for potentially confounding variables and changes in Hb
level over time.
These associations of higher achieved Hb with lower
mortality remain in contrast to a multicenter clinical trial
that randomized 1233 maintenance HD patients with car-
diac disease to therapy with epoetin and parenteral iron
that was intended to achieve a Hct of either 30% or 42%
[16]. The trial was halted early due to increased mortality
(not reaching the prespecified statistical stopping bound-
ary) among subjects randomized to the higher Hct arm.
The post-hoc observational analysis that, in each study
arm, higher mean achieved Hct was associated with lower
mortality does not rule out the possibility that raising
subjects’ Hb might increase mortality. If so, this could
plausibly be due to adverse effects of the treatment given
(e.g., higher epoetin and/or parenteral iron dosing) or
to an adverse effect of a rise in Hb level. The associa-
tions presented in Table 3, which are adjusted for prior
Hb level, epoetin dose, and iron dose, do not show an
association between elevated mortality and a rise in Hb
level after any particular epoetin/iron dosing combina-
tion. However, our analyses do not provide evidence for
or against a causal effect of any change in Hb level on
mortality. Further investigation, including novel analytic
approaches [30, 31, 39], may help to elucidate the com-
plex causal relationships among anemia, epoetin, and par-
enteral iron administered to treat anemia, changes in Hb
level in response to these treatments, and survival.
As in any observational study, unmeasured confound-
ing remains a possible explanation for our study results.
Despite modeling numerous morbidity and clinical care
characteristics not available in prior observational stud-
ies, we may not have fully accounted for all states of
ill health and aspects of patient care delivery that may
worsen anemia and independently contribute to mortal-
ity. For example, inflammatory states may be captured in-
completely by DOPPS variables, including high epoetin
dose, high ferritin level, and low albumin level. Therefore,
the possibility that low Hb level serves, at least in part, as
a marker for premortal illness in our observational study
but not in an effectively randomized clinical trial remains
a plausible explanation for the discrepancy between our
results and clinical trial findings [16, 26].
Our analyses do not provide support for the possibility
that the differences between our results and the multi-
center clinical trial findings [16] might be explained by
differences in study population. We considered this ex-
planation because the DOPPS was designed to be broadly
generalizable to the United States maintenance HD pop-
ulation, whereas the clinical trial was limited to patients
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with cardiac disease and included a higher than expected
proportion of subjects receiving HD via a synthetic graft.
However, the failure to detect interactions between Hb
level and known CVD (P = 0.43) or type of vascular ac-
cess (P = 0.67 for synthetic graft vs. all other types; P =
0.98 for arteriovenous fistula vs. all other types) indicates
that the associations of higher Hb with lower mortality in
our data do not differ according to presence or absence
of CVD or type of vascular access.
We chose to examine a series of interaction terms rep-
resenting the product of categorized Hb level and ESRD
vintage, CVD status, inflammatory markers, and other
health status indicators because we considered it plausi-
ble a priori that Hb level may be most strongly associated
with mortality in patients who are least stable clinically
or have greatest comorbidity burden. However, none of
these interaction terms were statistically significantly as-
sociated with mortality, providing no evidence that the
Hb-mortality relationship varies according to health sta-
tus. These findings imply that Hb levels <11 g/dL predict
increased mortality risk among all HD patients, not only
those with greatest measurable level of illness or comor-
bidity. Our findings also fail to support the contention
that the target Hb level should be tailored according to
comorbidity status [4–6], although inference is limited
about target Hb levels from this study of achieved Hb
levels.
Additionally, to our knowledge, this is the first study
to report whether the associations of Hb level with mor-
tality differ according to the time interval between Hb
level and the time at risk for mortality (lagged analyses,
Table 4). Because the associations of Hb levels <11 g/dL
with elevated mortality changed little with variations in
this time interval, patients with Hb <11 g/dL appear to
have elevated short- and longer-term mortality risk. For
Hb categories ≥12 g/dL, the decreasing hazard ratio for
mortality with increasing time interval between Hb level
and the time at risk raises the possibility that patients
who achieve “near-normal” Hb levels have especially
favorable longer-term prognosis. However, the possibil-
ity of any survival benefit for Hb categories ≥12 g/dL
compared to 11 to <12 g/dL should be considered spec-
ulative because these associations did not achieve con-
ventional levels of statistical significance. We also did not
examine the association with mortality of Hb levels more
than 6 months previously because of limitations in statis-
tical power. Nonetheless, the possibility that the ability
to achieve “near-normal” Hb levels predicts longer-term
survival merits further investigation.
CONCLUSION
This study of HD patients in the American arm of the
DOPPS Phase I examined the associations of Hb level
with mortality after accounting for numerous potentially
confounding time-updated morbidity and clinical care
characteristics not available in prior observational stud-
ies. Patients with Hb levels <11 g/dL had elevated mortal-
ity compared to those with higher Hb levels, and there was
no clear mortality difference among patients with Hb lev-
els ≥11 g/dL. These relationships varied somewhat with
changes in the time interval between Hb measurement
and the time at risk for mortality, but they did not change
according to ESRD vintage or indicators of health status.
Further investigation of the relationships among anemia,
treatment of anemia, and survival is warranted.
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